MedTrace Logo

Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C

NCT00512278 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2017-09-13

Study results available
· View outcomes & findings →

Summary

The aim of the study is to investigate in subjects receiving their first course of peg-interferon α-2b plus ribavirin therapy for chronic HCV infection

Conditions

  • Hepatitis C

Interventions

DRUG

Infliximab

Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Centocor, Inc.

    collaborator INDUSTRY

  • Nizar Zein

    lead OTHER

Principal Investigators

  • Nizar N Zein, MD · The Cleveland Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00512278 on ClinicalTrials.gov